Atossa Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $25.3M
- Price
- $2.54
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.93%
- Volume
- 25.7K
About
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Quick stats
Shares outstanding10.0M
Computed float7.7M
Float / shares77.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001488039
AI Summary
AI-generated1/18
minormixedearnings
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Atossa reported a Q2 net loss of $8.5 million, narrowing slightly from the prior year, while cash reserves decreased to $26.1 million from $41.3 million at the end of 2025.
To fund operations, the company closed a registered direct offering raising $4.5 million upfront, with the potential for an additional $12 million if warrants are fully exercised.
Operationally, the company completed enrollment in its Phase 2 EVANGELINE trial for breast cancer and presented data supporting (Z)-endoxifen's potential in Duchenne Muscular Dystrophy and McCune-Albright Syndrome.
Red flags
- Cash balance decreased significantly from $41.3M to $26.1M over six months
- Dilutive financing involving issuance of common stock and warrants